Colon Cancer :: Rice bran could reduce risk of intestinal cancer
A study by biomedical scientists at the University of Leicester has revealed for the first time that rice bran could reduce the risk of intestinal cancer.
Gastrointestinal
Crohn’s Disease :: Remicade – Treatment for Pediatric Crohn’s Disease
Centocor, Inc. and Schering-Plough Corporation (NYSE: SGP) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending the approval of REMICADE(R) (infliximab) for the treatment of severe, active Crohn’s disease (CD) in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy, or who are intolerant to, or have contraindications for, such therapies.
Atherosclerosis :: Crestor effective at halting early atherosclerosis
An international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting early changes in the blood vessels that can lead to atherosclerosis.
Kidney Cancer :: Sutent achieves first line EAU approval for kidney cancer
Sutent (sunitinib malate) has received a European Association of Urology recommendation, as first-line therapy in patients with metastatic renal cell carcinoma of good and intermediate risk, just two months after gaining EU marketing authorization for first line use in all patients with advanced and/or metastatic renal cell carcinoma.
Ulcerative Colitis :: LIALDA – the first oral once-daily mesalamine for ulcerative colitis available
Shire plc today announced the availability of LIALDATM (mesalamine) with MMXTM Technology, indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC), a type of inflammatory bowel disease. LIALDA is the first and only FDA-approved once daily oral formulation of mesalamine. The US Food and Drug Administration approved LIALDA on Jan. 16, 2007.
Pediatrics :: Most children in US hospitals receive medicines off-label
Nearly four out of five hospitalized children receive medications that have been tested and approved only for adults, according to a study of hundreds of thousands of patient records. This so-called “off-label” use of drugs was thought to be especially common in children, and the new research, the largest-ever U.S. pediatric study, confirms this.
Gene :: Genetic analyis for personalizing of treatment of lung and colon cancer, certain sarcomas
Genetic analysis has enabled the personalising of the pharmaceutical treatment of patients with cancer, enhancing thereby therapeutic efficacy and minimising possible toxicity.
Vomiting :: FDA approves first medication to treat and prevent vomiting in dogs
Pfizer Animal Health (PAH) announced the U.S. Food and Drug Administration (FDA) has approved Cerenia(TM) (maropitant citrate), the first medication to prevent and treat acute vomiting in dogs.
Clostridium difficile :: Trillium Health Centre steps up to stop C. difficile
Trillium Health Centre, which serves the communities of Mississauga and Toronto, is currently experiencing an increase in the number and severity of adult patient cases with Clostridium difficile or C. difficile.
Heart Disease :: Painkillers raise heart disease risk
Many doctors should change the way they prescribe pain relievers for chronic pain in patients with or at risk for heart disease based on accumulated evidence that nonsteroidal anti-inflammatory drugs (NSAIDs), with the exception of aspirin, increase risk for heart attack and stroke, according to an American Heart Association statement published in Circulation: Journal of the American Heart Association.